NovaBay Pharmaceuticals, Inc.
NBY
Price:
$0.681
Market Cap:
$3.33M
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was former...[Read more]
Industry
Biotechnology
IPO Date
2007-10-26
Stock Exchange
AMEX
Ticker
NBY
PE Ratio
[-0.01]
ROE
[-1030.19%]
Current Ratio
[1.15]
Dividend Yield
[0%]
Enterprise Value
[3.81M]
Dividend History
The ROE as of November 2024 (TTM) for NovaBay Pharmaceuticals, Inc. (NBY) is -1030.19%
According to NovaBay Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -1030.19%. This represents a change of 107.19% compared to the average of -497.22% of the last 4 quarters.
NovaBay Pharmaceuticals, Inc. (NBY) Historical ROE (quarterly & annually)
How has NBY ROE performed in the past?
The mean historical ROE of NovaBay Pharmaceuticals, Inc. over the last ten years is -272.96%. The current -1030.19% ROE has changed 277.41% with respect to the historical average. Over the past ten years (40 quarters), NBY's ROE was at its highest in in the March 2020 quarter at 453.30%. The ROE was at its lowest in in the September 2015 quarter at -2309.25%.
Average
-272.96%
Median
-169.66%
Minimum
-1077.80%
Maximum
372.17%
NovaBay Pharmaceuticals, Inc. (NBY) ROE by Quarter and Year
Discovering the peaks and valleys of NovaBay Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 715.80%
Maximum Annual ROE = 372.17%
Minimum Annual Increase = -149.76%
Minimum Annual ROE = -1077.80%
| Year | ROE | Change |
|---|---|---|
| 2023 | -290.89% | 88.75% |
| 2022 | -154.11% | 138.98% |
| 2021 | -64.49% | -28.04% |
| 2020 | -89.62% | -91.69% |
| 2019 | -1077.80% | 715.80% |
| 2018 | -132.12% | -53.71% |
| 2017 | -285.39% | 54.10% |
| 2016 | -185.20% | -149.76% |
| 2015 | 372.17% | -145.27% |
| 2014 | -822.19% | 336.46% |
NovaBay Pharmaceuticals, Inc. (NBY) Average ROE
How has NBY ROE performed in the past?
The current ROE of NovaBay Pharmaceuticals, Inc. (NBY) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-169.83%
5-year avg
-335.38%
10-year avg
-272.96%
NovaBay Pharmaceuticals, Inc. (NBY) ROE vs. Peers
How is NBY’s ROE compared to its peers?
NovaBay Pharmaceuticals, Inc.’s ROE is greater than Immix Biopharma, Inc. (-102.10%), less than CNS Pharmaceuticals, Inc. (695.91%), less than eFFECTOR Therapeutics, Inc. (2.18%), greater than Navidea Biopharmaceuticals, Inc. (-173.56%), greater than Sonnet BioTherapeutics Holdings, Inc. (-398.33%), greater than ZyVersa Therapeutics, Inc. (-25512.50%), greater than VectivBio Holding AG (-56.92%), less than AVROBIO, Inc. (29.68%), greater than Zura Bio Limited (-39.61%), less than Altamira Therapeutics Ltd. (783.37%), greater than Enveric Biosciences, Inc. (-201.01%), greater than Palisade Bio, Inc. (-148.31%), greater than Phio Pharmaceuticals Corp. (-134.57%),
| Company | ROE | Market cap |
|---|---|---|
| -102.10% | $49.14M | |
| 695.91% | $7.15M | |
| 2.18% | $941.00 | |
| -173.56% | $100.08K | |
| -398.33% | $2.50M | |
| -25512.50% | $2.65M | |
| -56.92% | $1.06B | |
| 29.68% | $5.24M | |
| -39.61% | $178.25M | |
| 783.37% | $1.60M | |
| -201.01% | $3.31M | |
| -148.31% | $3.24M | |
| -134.57% | $2.61M |
Build a custom stock screener for NovaBay Pharmaceuticals, Inc. (NBY) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NovaBay Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
NovaBay Pharmaceuticals, Inc. (NBY) and other stocks custom spreadsheet templates
The easiest way to analyze a company like NovaBay Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is NovaBay Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for NovaBay Pharmaceuticals, Inc. (NBY)?
What is the highest ROE for NovaBay Pharmaceuticals, Inc. (NBY)?
What is the 3-year average ROE for NovaBay Pharmaceuticals, Inc. (NBY)?
What is the 5-year average ROE for NovaBay Pharmaceuticals, Inc. (NBY)?
How does the current ROE for NovaBay Pharmaceuticals, Inc. (NBY) compare to its historical average?